The advantages of biosimilars – clinically equivalent versions of high-price biologic drugs – have been known for years. But despite their growing availability, adoption remains slow… in no small part because major PBMs are stifling uptake. Fortunately, MedBen Rx offers a better path to biosimilars’ cost-saving potential.
Per Forbes: “[E]ven after a year on the market, the average biosimilar commands just under 20% market share for its therapeutic line. PBMs frequently exclude these lower-cost – and thus lower-rebate – biosimilars from formularies or lock them behind prior authorization and ‘fail-first’ requirements.
“In cases when PBMs do include biosimilars in their formularies, they’re often artificially pricey ‘private-label’ drugs affiliated with the PBMs themselves.”
MedBen Rx ensures direct-to-consumer pricing on popular biosimilars, giving employers and members access to affordable, high-quality medications without the PBM games. As more biosimilars enter the market, we’ll continue to make them available at the lowest possible cost.
If you’re a current MedBen Rx client and haven’t yet opted into our biosimilar program, just reach out to your Account Management team. Not a client yet? We’d love to show you how we do things differently. Contact your broker or call MedBen Marketing to learn more.